| 22726 | PC | Packed Red Blood Cells | Packed Cells, Leukoreduced Red Cells, LRBC, RBC, PRBC | ABO/RH, ABSC, CROSSMATCH | | 24709 | PCS10 | Pain Clinic Drugs with Confirmation | Amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin, Amines
| Immunoassay screen with quantitative confirmation by liquid chromatography methods (when needed) for the following drug classes or method groups: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiate method group, oxycodone method group, and buprenorphine. Test also includes specimen validity testing (creatinine) to detect adulteration, dilution, or substitution of the specimen. Immunoassay screen for ethanol with quantitative result.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 24726 | PCS10WO | Pain Clinic Drugs without Confirmation | amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine
| Immunoassay screen for the following drug classes or method groups: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine. Test also includes specimen validity testing (creatinine) to detect adulteration, dilution, or substitution of the specimen.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 26153 | PCS4WO | Pain Clinic Survey 4 Without Confirmation, Urine | Drug screen, drug test, barbiturates, cannabinoids, marijuana, THC, cocaine, ethanol
| Immunoassay screen for the following drug classes or method groups: barbiturates, cannabinoids, cocaine, and ethanol. Test also includes specimen validity testing (creatinine) to detect adulteration, dilution, or substitution of the specimen.
Results of this test are presumptive. If confirmatory testing is desired, the confirmatory test(s) can be ordered as add-on (u-have) tests, utilizing the original urine collection, within 9 days of the original test.
This test is intended to compliment the test “Targeted Drug Panel, Urine” (TDPU).
| | 26661 | PANELA | Pancreatic Elastase, Fecal | PE1, Elastase, Pancreatic, Pancreatic Elastase
| | | 24817 | HPPSO | Pancreatic Polypeptide, Plasma (HPP) | HPP (Human Pancreatic Polypeptide), Human Pancreatic Polypeptide, PP (Pancreatic Polypeptide,Plasma)
| | | 26386 | PANEXSO | Panorama Extended Panel | Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Triploidy, 22q11.2 Deletion, 1p36 Deletion, Cri-du-chat Syndrome, Prader-Willi Syndrome, Angelman syndrome, Chromosome abnormalities, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Klinefelter Syndrome, Triple X Syndrome, Jacob's Syndrome | The Panorama Extended Panel includes the screening that is offered by the Panorama Prenatal Panel (Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X and Triploidy), as well as additional screening for microdeletion conditions including 22q11.2 deletion syndrome, 1p36 deletion, Cri-du-chat syndrome, Prader-Willi syndrome and Angelman syndrome. | | 26385 | PANORSO | Panorama Prenatal Panel | Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Triploidy, 22q11.2 Deletion, Chromosome abnormalities, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Klinefelter Syndrome, Triple X Syndrome, Jacob's Syndrome | | | 23152 | PARASO | Paraneoplastic Autoantibody Evaluation, Serum (PAVAL) | AGNA, Amphiphysin Antibody, Serum, ANNA (Antineuronal Nuclear Antibody), Anti-CV2, Anti-Enteric Neuronal Antibody, Anti-Glial Nuclear Antibody, Anti-Hu, Anti-Purkinje Cell Cytoplasmic Antibodies, Anti-Ri, Anti-Yo, Antineuronal, APCA (Anti-Purkinje Cell Antibodies), Calcium Channel Blockers, Cerebellar Antibodies, Cramp-fasciculation, CRMP-5, IgG, Hu Antibody, Myoid Antibody, Neuromyotonia, Neuronal Nuclear Antibody, Neuronal Nuclear Antibody Panel, Neuronal Potassium Channel Ab, Neuronal-Anti, Ovarian Cancer-Related Antibodies, P/Q Type Calcium Channel Antibody, Paraneoplastic Antibodies, Paraneoplastic Autoantibody Evaluation, Paraneoplastic Neurological Autoimmunity, PCA-1 (Purkinje Cell Cytoplasmic Antibodies), PCA-2 (Purkinje Cell Cytoplasmic Antibodies), PCA-Tr (Purkinje Cell Cytoplasmic Antibodies), PCAb (Purkinje Cell Cytoplasmic Antibodies), Potassium Channel Antibodies (specify), Purkinje Cell Cytoplasmic Antibodies, Type 1, Purkinje Cell Cytoplasmic Antibodies, Type 2, Purkinje Cell Cytoplasmic Antibodies, Type Tr, Ri, Anti, VGCC (Voltage-Gated Calcium Channel) Antibodies, VGKC, VGPC, Voltage-Gated Potassium Channel Ab, Yo-Anti, Collapsin Response-Mediator Protein-5 Antibody (CRMP-5), Isaacs Disease, Neuromuscular Hyperexcitability, Purkinje Cell Cytoplasmic Antibodies, Conotoxin Receptor Antibodies
| | | 26607 | PVLESO | Paraneoplastic Vision Loss Evaluation, Serum (PVLE) | CRMP-5; Anti-CV-2; Recoverin; Retinopathy; Ophthalmitis; Anti-CAR; CAR
| | | 26467 | PAC1SO | Paraneoplastic, Autoantibody Evaluation, Spinal Fluid (PAC1) | Amphiphysin Ab, CSF, ANNA-1, CSF, ANNA-2, CSF, ANNA-3, CSF, Anti-Hu, Antineuronal Cerebellar Antibodies, CRMP-5-IgG, CSF, Dorsal Root Ganglion Antibody, Hu Antibody, Neuron Restricted Autoantibodies, Neuronal Nuclear Antibody, Neuronal-Anti, Ovarian Cancer-Related Antibodies, Paraneoplastic Autoantibody Western Blot Confirmation, CSF, Paraneoplastic Neurological Autoimmunity, PCA-1, CSF, PCA-2, CSF, PCA-Tr, CSF, Purkinje Cell Cytoplasmic Antibodies, Ri, Anti, Yo-Anti
| | | 23103 | IOPTH | Parathyroid Hormone, Intraoperative Rapid | Parathyroid Surgery Only, IOPTH
| | | 25487 | MISC | Parechovirus PCR, CSF | Entero-Parechovirus, HPeV, Enterovirus | | | 26014 | PPAPSO | Parental Prenatal Array Prep Test (PPAP) | | | | 26639 | PCABSO | Parietal Cell Antibodies, IgG, Serum (PCAB) | | | | 26618 | MISC | Paroxysmal Nocturnal Hemoglobinuria, PI-Linked Antigen, Blood (PLINK) | Acid Hemolysin; CD55; CD59; FLAER; GPI-Linked Antigen; Ham-Crosby Sugar-Water Test, Blood; Hemolytic Anemia; Paroxysmal Nocturnal Hemoglobinuria (PNH); PI Linked Antigen; Sucrose Analysis; Sucrose Fragility; Sucrose Hemolysis; Sugar Water PNH Screen; Sugar Water Test, Ham-Crosby, Blood
| | | 26352 | FPRTFSO | Parrot Australian (Budgerigar) Feathers IgE (FPRTF) | Animal Allergen Australian (Budgerigar) Quaker | | | 22759 | APTT | Partial Thromboplastin Time - APTT/PTT | PTT, APTT, Activated Partial Thromboplastin Time
| | | 22758 | PTTLA | Partial Thromboplastin Time - Lupus Anticoagulant (PTTLA) | PTT-LA, Lupus Anticoagulant PTT, APTT-LA, StaClot LA | | | 26116 | PARVSSO | Parvovirus B19 Antibodies, IgG and IgM, Serum (PARVS) | B19, Erythrovirus B19, Fifth Disease, Human Parvovirus, Slapped Cheek disease | Parvovirus B19 IgG & IgM Antibodies with Interpretation | | 23392 | MISC | Parvovirus B19, Molecular Detection, PCR, Varies (PARVO) | B19, Erythrovirus B19, Fifth Disease-Parvovirus, Human Parvovirus B19, Parvovirus B19 PCR, Parvovirus PCR, Parvovirus-Fifth Disease
| | | 26054 | PARVPSO | Parvovirus B19, PCR, Plasma (PARVP) | B19, Erythrovirus B19, Fifth Disease-Parvovirus, Human Parvovirus B19, Parvovirus B19 PCR, Parvovirus PCR, Parvovirus-Fifth Disease | | | 26406 | PDGFSO | PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue (PDGF) | COL1A1-PDGFB COL1A1/PDGFB DFSP/GCF t(17;22) | This test does not include a pathology consultation. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge. This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. | | 25648 | MISCTIS | PD-L1 28-8 FDA (OPDIVO/Nivolumab) | PD-L1, PDL1, 28-8 FDA, CHECKMATE, OPDIVO | | | 25649 | MISCTIS | PD-L1, SP142 FDA (TECENTRIQ/atezolizumab) IHC | PD-L1, PDL1, SP142, TECENTRIQ, ATEZOLIAUMAB, IHC, Immunohistochemistry | | | 22762 | HD-PDF | Peritoneal Equilibration Test | Hemodialysis PDF, Glu/Creat/UreaN | Glucose, Creatinine, and Urea Nitrogen | | 22763 | MISC | Peroxidase Stain | Myeloperoxidase | | | 26288 | APH | pH, Arterial | | | | 22765 | PH-BF | pH, Body Fluid | | | | 22767 | PH-U | pH, Urine Qualitative | | | | 26289 | VPH | pH, Venous | | | | 22769 | PHENO | Phenobarbital | Phenobarb
| | | 26097 | PKUSO | Phenylalanine and Tyrosine, Plasma (PKU) | Phenylalanine Includes Tyrosine
PKU (Phenylketonuria)
Tyrosine
Tyrosinemia
Hyperphenylalaninemia
| Phenylalanine and Tyrosine | | 22772 | PTN | Phenytoin | Dilantin, DPH, Diphenylhydantoin
| | | 26603 | PNYFSO | Phenytoin, Free, Serum (PNYF) | Dilantin Free, Serum
Free Dilantin
Free Dilantin, Serum
Free Phenytoin
Dilantin, Total and Free (ORDER PNTFT)
| | | 26253 | BLPATCH | Phlebotomy Draw - Blood Patch | | | | 26573 | PETHCSO | Phosphatidylethanol Confirmation, Blood (PETH) | 1-Palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanol (PLPEth) 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol (POPEth)
| | | 25221 | PSIGM | Phosphatidylserine IgM | | | | 26576 | PLA2ISO | Phospholipase A2 Receptor, Immunofluorescence, Serum (PLA2I) | | | | 26588 | PLA2MSO | Phospholipase A2 Receptor, Monitoring, Enzyme-Linked Immunosorbent Assay, Serum | | | | 22776 | PHOS | Phosphorus | PO4, Inorganic Phosphorus, Phos, Phosphate
| | | 22777 | PH-24H | Phosphorus, Urine 24 Hour | Phosphorus - Urine, 24hr | | | 22778 | PHOS-RU | Phosphorus, Urine Random | PO4-RU | | | 22779 | PINW | Pinworm | Enterobius vermicularis, Pinworm Paddle
| | | 25240 | PIPASO | Pipecolic Acid, Serum (PIPA) | | | | 22645 | PLASMA | Plasma | FFP, Fresh Frozen Plasma | | | 24744 | PCPDFSO | Plasma Cell Proliferative Disorder FISH, Bone Marrow (PCPDS) | +1q or 1q22, 17p- (17p deletion) or TP53, IGH (14q32) rearrangement, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, Plasma Cell Leukemia, t(11;14) - CCND1/IGH, t(14;16) - IGH/MAF, t(14;20) - IGH/MAFB, t(4;14) - FGFR3/IGH | | | 25601 | PLASFSO | Plasma Cell Proliferative FISH, Tissue (PLASF) | 17p- (17p deletion) or TP53, IGH (14q32) rearrangement, Monoclonal Gammopathy of Unknown Significance (MGUS), Multiple Myeloma, Plasma Cell Leukemia, t(4;14) - FGFR3/IGH, t(11;14) - CCND1/IGH, t(14;16) - IGH/MAF, t(14;20) - IGH/MAFB, +1q or 1q22
TI PLASFSO
| | | 26578 | PFHGB | Plasma Free Hemoglobin | | | | 26608 | PGL3SO | Plasma GL-3 (504662) | Fabrazzyme biomarker, Fabry disease biomarker
| | | 25542 | PLHBBSO | Plasma Hemoglobin (PLHBB) | Plasma Free Hemoglobin Plasma Hemoglobin | | | 26254 | MISC | Plasminogen Activator Inhibitor Antigen, Plasma (PAI1) | | | | 25464 | PLGSO | Plasminogen Activity, Plasma (PSGN) | Plasminogen, Functional, Plasma
| | | 22784 | PLTAGG | Platelet Aggregation | | Agonsists tested: Epinephrine, ADP, Ristocetin, Collagen and Arachidonic Acid | | 24917 | APASO | Platelet Antibody Screen (5543) | Ref Lab Code: 5543, Anti-Platelet Antibodies | | | 22954 | PPR-PPS | Platelet Concentrate | SDP, Single Donor Platelet, Apheresis collected platelet | | | 22955 | PLT | Platelet Count | Thrombocyte
| | | 22956 | PFT-EPI | Platelet Function Test | PFA-100, Platelet Function Assay-100
| | | 26161 | PLM6S | Platelet Mapping on TEG6S | PLM, PLM6S, Platelet Mapping ADP, Platelet Mapping AA
| HKH-MA, ActFMA, ADP-MA, %INH-ADP, %AGG-ADP, AA-MA, %INH-AA, %AGG-AA | | 26457 | PTEMSO | Platelet Transmission Electron Microscopic Study, Whole Blood (PTEM) | | | | 24998 | PMLSO | PML/RARA Quantitative, PCR (PMLR) | (15;17)(q22;q12), Acute myeloid leukemia (AML), Acute promyelocytic leukemia (APL), AML (acute myeloid leukemia), AMPL, APL minimum residual disease, PCR, PML/RARA, ABC
| | | 25534 | MISC | PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative (2002871) | AMPL' APL, APL MRD, APL Post-consolidation therapy testing, PML-RARA fusion types, A, B, B variant, PML-RARA long, short, variable types, PML-RARA S, L, V forms, PML_RARA fusion types, Quantitative PML, t(15;17) | | | 26455 | PNRPSO | Pneumocystis jiroveci, Molecular Detection, PCR, Varies (PNRP) | | | | 25060 | POLIOSO | Poliovirus (Types 1, 3) Antibodies, Neutralization (FPOLO) | Polio Immune Status Panel, Polio Vaccine Response, Poliovirus
| Polio 1, 3 Titers | | 26390 | FPOLESO | Pollock White (Pollachius virens) IgE (FPOLE) | Pollachius virens, Pollock White (Pollachius virens) IgE (FPOLE) | | | 26348 | PVJAKSO | Polycythemia Vera, JAK2 V617F with Reflex to JAK2 Exon 12-15, Sequencing for Erythrocytosis, Varies (PVJAK) | JAK2 V617F
JAK2 exon 12 Polycythemia Vera Myeloproliferative Neoplasm (MPN) | The algorithm starts with a highly sensitive DNA-based JAK2 V617F test by allele specific polymerase chain reaction. If the JAK2 V617F result is negative or very low positive (0.06% - 2%), JAK2 exon 12-15 Sanger sequencing test will be performed on the stored RNA sample. If a JAK2 V617F mutation (>2%) is detected, the algorithm stops and no further testing will be performed. The Sanger sequencing covers JAK2 exons 12 through the first 90% of exon 15, which spans the region containing essentially all mutations reported in myeloproliferative neoplasms.
| | 22960 | PBG-QL | Porphobilinogen, Qualitative, Random Urine | PBG Qual
| | | 26272 | PBGUSO | Porphobilinogen, Quantitative, Random, Urine (PBGU) | Acute Intermittent Porphyria (AIP)
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Variegate Porphyria (VP) Porphobilinogen Qnt, U (PBGU) U PBGUSO | | | 22962 | PEESO | Porphyrins Evaluation, Whole Blood (PEE) | Erythrocyte Porphyrin, Erythropoietic Protoporphyria (EPP), Free Erythrocyte Porphyrin (FEP), Protoporphyrin, Protoporphyrins, Total, Erythrocytes, RBC Porphyrins, Red Blood Cell Porphyrins, X-linked Dominant Protoporpyria (XLDPP or XDP)
| | | 23105 | PORPHU | Porphyrins, Quantitative, 24 Hr Urine (PQNU) | Acute Intermittent Porphyria (AIP)
Congenital Erythropoietic Porphyria (CEP)
Coproporphyrin
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Porphyria Cutanea Tarda (PCT)
Porphyrins, Fractionation, Urine
Uroporphyrin
Variegate Porphyria (VP) 24 PORPHU
| | | 25003 | POSACSO | Posaconazole, Serum (POSA) | Noxafil (Posaconazole), Posaconazole (Noxafil)
| | | 22964 | K | Potassium | K, i-Stat Potassium
| | | 22963 | K-O | Potassium, Other | .K-Other, Body Fluid Potassium | | | 22965 | K-24H | Potassium, Urine 24 Hour | K-24H
| | | 22966 | K-RU | Potassium, Urine Random | Potassium-Rand Ur
| | | 22967 | PREALB | Prealbumin | Thyroxine-binding prealbumin, transthyretin, PAB
| | | 26623 | AD2ARSO | Precivity AD2, Reflex to Apolipoprotein E, Plasma (AD2AR) | AB42/40 Ratio; Alzheimer's; Amyloid Beta; Amyloid Probability Score2; APOE; Dementia; Mild cognitive impairment; p-tau217; p-tau217 Ratio; Percent p-tau217; %p-tau217; C2N
| The PrecivityAD2 blood test measures amyloid beta (Abeta) 42/40 ratio and percent tau phosphorylated at threonine-217 (%p-tau217). The results are then combined and used in a proprietary statistical algorithm to calculate the Amyloid Probability Score 2 (APS2). The APS2, Abeta 42/40 ratio and %p-tau217 are reported, however, individual Abeta42, Abeta40, phosphorylated tau217 and non-phosphorylated tau217 concentrations are not reported. For patients who receive a positive PrecivityAD2 test result, additional testing is performed to measure the apolipoprotein E isoforms E2, E3, and E4.
| | 26624 | C2AD2SO | PrecivityAD2, Plasma (C2AD2) | AB42/40 Ratio; Alzheimer's; Amyloid Beta; Amyloid Probability Score2; APOE; Dementia; Mild cognitive impairment; p-tau217; p-tau217 Ratio; Percent p-tau217; %p-tau217; C2N
| The PrecivityAD2 blood test measures amyloid beta (Abeta) 42/40 ratio and percent tau phosphorylated at threonine-217 (%p-tau217). The results are then combined and used in a proprietary statistical algorithm to calculate the Amyloid Probability Score 2 (APS2). The APS2, Abeta 42/40 ratio and %p-tau217 are reported, however, individual Abeta42, Abeta40, phosphorylated tau217 and non-phosphorylated tau217 concentrations are not reported.
| | 24816 | PGABSO | Pregabalin (PGN) | Lyrica®
| | | 22968 | PGSER | Pregnancy Test, Stat | Pregnancy, HCG, Rapid
| | | 22969 | PGQL | Pregnancy Test, Urine Qualitative | Rapid Slide Pregnancy Test, HCG, Urine, Qualitative
| | | 25298 | PREGNSO | Pregnenolone, Serum (PREGN) | | | | 23215 | AFPADSO | Prenatal Aneuploidy Detection, FISH (PADF) | Ambiguous Genitalia
FISH For Prenatal Aneusomy
Trisomy 13 (Patau Syndrome)
Trisomy 18 (Edwards Syndrome)
Trisomy 21 (Down Syndrome)
Turner Syndrome, FISH
XXY, XXX, or XYY
Prenatal aneuploidy Amnio Aneuploidy FISH SO (PADF) AF PADSO | Prenatal Aneuploidy Detection, FISH This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. | | 26516 | PMND1SO | Primary Membranous Nephropathy Diagnostic Cascade, Serum | Anti-PLA2R, PLA2R, Anti-THSD7A, Thrombospondin, THSD7
| | | 22972 | PRIMSO | Primidone (101) | Mysoline® | | | 22973 | PROCSO | Procainamide and NAPA (PA) | NAPA (N-Acetyl Procainamide), Pronestyl (Procainamide), N-Acetyl Procainamide
| | | 25166 | PCT | Procalcitonin, Serum | | | | 25679 | PINPSO | Procollagen I Intact N-Terminal, Serum (PINP) | | Procollagen I Intact N-Terminal
| | 22974 | PROGES | Progesterone | P4
| | | 23352 | PROINSO | Proinsulin, Plasma (PINS) | Proinsulin, P
| | | 22975 | PROLAC | Prolactin | | | | 26637 | FPDPGSO | Prostaglandin D2 (PGD2)(FPDPG) | FPDPG, PGD2, Prostaglandins, Prostaglandins PGD2
| | | 22981 | PROT-CF | Protein C Activity (Functional) | | | | 22229 | | Protein C Antigen | | | | 26125 | PCAGSO | Protein C Antigen, No Coumadin (PCAG) | | | | 22983 | PROT-CM | Protein C Antigen, On Coumadin (500534) | Protein C Antigen, Protein C Antigen / Factor VII ratio
| Test includes Protein C antigen, Factor VII antigen, and Prot C/Factor VII ratio. | | 26501 | PEP | Protein electrophoresis, Serum (See test code IEPIT: Protein-Immunotyping (PEP,GAM,IT) Panel (IEPIT)) | | | | 22230 | | Protein S Antigen | | | | 22985 | PROTSI | Protein S Antigen (Free), No Coumadin | | | | 22986 | PROT-SM | Protein S Antigen, On Coumadin (500530) | Protein S Antigen, Protein S Antigen/Factor VII Antigen Ratio
| Test includes Protein S antigen, Factor VII antigen, and Prot S/Factor VII ratio. | | 22987 | TP-O | Protein, Body Fluid | Body Fluid Total Protein, TP-O | | | 22988 | CSFTP | Protein, CSF Fluid | Spinal Fluid Protein
| | | 22989 | TP | Protein, Total | Protein, Total - Blood
| | | 22172 | PROT-U | Protein, Urine | Urine Protein screen, Protein, Urine, Qualitative, Albumin, Urine Qualitative
| | | 22990 | PRO-24H | Protein, Urine 24 Hour | Protein -24Hr Urine
| Urine Protein and Creatinine | | 25124 | PRO-6H | Protein, Urine 6 Hour | Protein, Urine, Quantitative, 6 hours, 6 HR | Urine Protein and Creatinine | | 22991 | ORTHO | Protein, Urine, Orthostatic Proteinuria | Orthostatic Proteinuria | Urine Protein and Creatinine | | 22992 | PRO-CR | Protein/Creatinine Ratio, Urine | PR/CR, Random Urine Quantitative Protein
| Urine Protein and Creatinine | | 23123 | PR3 | Proteinase 3 Antibody | Serine Protease 3, PR3 ANCA
| | | 25507 | GAMPRIT | Protein-Immunotyping (PEP,GAM,IT) and Beta 2 Microglobulin | Gammopathy profile, Monoclonal gammopathy profile, IF-B2 panel, Quantitative immunoglobulins in serum (IgG, IgA and IgM) with serum protein electrophoresis and Beta-2 Microglobulin
| IgG, IgA, IgM, Protein electrophoresis (Total Protein, Albumin, Alpha-1, Alpha-2, Beta and Gamma fractions), Beta-2 Microglobulin and total serum protein. Immunotyping may be ordered by interpreter, at an additional charge. | | 25508 | IEPIT | Protein-Immunotyping (PEP,GAM,IT) Panel | IF Panel (if Immunotyping is required by interpreter), IEP, Immunoelectrophoresis panel - includes protein electrophoresis, immunoglobulins IgG, IgA and IgM and Immunotyping if needed). IT Panel
| Protein Electrophoresis (Total Protein, Albumin, Alpha-1, Alpha-2, Beta, and Gamma Globulins), Immunoglobulin IgG, IgA and IgM. Immunotyping, if required by interpreter (there is an additional charge for Immunotyping). | | 23001 | PTG | Prothrombin Gene Mutation | PTG 20210, Prothrombin Gene Mutation (PTG), Hypercoagulability,
Thrombophilia | | | 23002 | PT | Prothrombin Time - INR | Protime, PT, INR, CSPT, CS PT, Code Stroke PT, Code Stroke Protime
| | | 22643 | MISC | Protoporphyrins, Fractionation, Erythrocytes (PPFE) | EPP (Erythropoietic Protoporphyria), Erythropoietic Protoporphyria, Free Protoporphyrin, Zinc Protoporphyrin, X-linked Dominant Protoporphyria (XLDPP or XDP)
| | | 23003 | MISC | Protriptyline (110) | Vivactyl® | | | 23004 | PSA-F | PSA, Free & Total | Prostate Specific Antigen, Free & Total
| Total Prostate Specific Antigen , Free Prostate Specific Antigen | | 23005 | PSA | PSA, Total | Prostate Specific Antigen, Total
| | | 26332 | PSA-H | PSA, Total Hybritech | Prostate Specific Antigen, Total Hybritech
| | | 24892 | PCHOTSO | Pseudocholinesterase, Total (PCHE1) | Cholinesterase (Pseudo), Total, Serum Cholinesterase (Pseudochol), Butyrylcholinesterase
| | | 26662 | PTH | PTH, Intact | | | | 25117 | PTH-O | PTH, Intact - Other Fluids | FNA, Fine Needle Aspirate, Parathyroid Hormone, Fluid, Cyst, PTH | | | 22925 | INT-PTH | PTH, Intact With Calcium | Intact PTH, I-PTH, CA-PTH with minerals
| Parathyroid Hormone, Calcium | | 23250 | PTHRSO | PTH-Related Peptide (PTHRP) | Humoral Hypercalcemia of Malignancy Factor
Parathyroid Related Polypeptide
Parathyroid Related Protein
PRP
PTH Related Peptide
PTHRP, Plasma
PTH Related Protein
Parathyroid Hormone Related Peptide | | | 26424 | PUPYUSO | Purines and Pyrimidines Panel, Urine (PUPYU) | Adenine, Adenosine, Deoxyadenosine, Deoxyguanosine, Deoxyinosine, Guanosine, Hyperuricemias, Hypoxanthine, Inosine, Orotic Acid, Pyrimidine, Succinyladenosine, Thymidine, Uracil, Thymine, Uric Acid, Uridine, Xanthine, S-Sulfocysteine, Adenine phosphoribosyltransferase deficiency, Adenosine deaminase deficiency, Adenosine monophosphate deaminase deficiency, Adenylosuccinate lyase deficiency, AICAr transformylase/imp cyclohydrolase deficiency, Beta-ureidopropionase deficiency, Carbamoyl phosphate synthetase deficiency, Deoxyguanosine kinase deficiency, Dihydropyrimidinase deficiency, Dihydropyrimidine dehydrogenase deficiency, Hyperornithinemia-hyperammonemia-homocitrullinuria, Lesch-Nyhan syndrome, Molybdenum cofactor deficiency, Phosphoribosyl pyrophosphate synthetase deficiency, Primary hyperoxaluria, Purine metabolism disorders, Purine nucleoside phosphorylase deficiency, Pyrimidine metabolism disorders, Secondary hyperuricemia, Sulfite oxidase deficiency, Thymidine phosphorylase deficiency, Uridine monophosphate synthetase deficiency, Xanthine dehydrogenase and xanthine aldehyde oxidase dual deficiency, Xanthine dehydrogenase deficiency, Xanthine dehydrogenase/xanthine aldehyde oxidase/sulfite oxidase combined deficiency | Uracil, Thymine, Adenine, Hypoxanthine, Xanthine, Orotic, Dihydroorotic Acid, Uric Acid, Deoxythymidine, Deoxyuridine, Thymidine, Uridine, Deoxyadenosine, Deoxyinosine, Deoxyguanosine, Adenosine, Inosine, Guanoasine, 5-Aminoimidazole-4-carboxyamide 1-beta-D-ribofuranoside (AICAR), Succinyladenosine, S-Sulfocysteine, Dihydrouracil, Dihydrothymine, N-carbomoyl-B-alanine, N-carbomoyl-B-aminoisobutyric Acid | | 22847 | PYRUV | Pyruvate in Blood | Pyruvid Acid, Pyruvate in whole blood | | | 25658 | PYRSO | Pyruvic Acid, Blood (PYR) | ETC, Mitochondrial Electron Transport Chain Defects, Mitochondrial Respiratory Chain Disorders, PC, PDH (Pyruvate Dehydrogenase) Deficiency, PDHC (Pyruvate Dehydrogenase Complex), Pyruvate Carboxylase Deficiency, Pyruvate Decarboxylase Deficiency, Pyruvate Dehydrogenase (PDH) Deficiency, Pyruvate Dehydrogenase Complex (PDHC), blood pyruvate
| | | 25603 | PYRCSO | Pyruvic Acid, CSF (PYRC) | ETC; Mitochondrial Electron Transport Chain Defects; Mitochondrial Respiratory Chain Disorders; PC; PDH (Pyruvate Dehydrogenase) Deficiency; PDHC (Pyruvate Dehydrogenase Complex); Pyruvate; Pyruvate Carboxylase Deficiency; Pyruvate Dehydrogenase (PDH) Deficiency; Pyruvate Dehydrogenase Complex (PDHC); Pyruvate, Spinal Fluid; LP; C PYRCSO | |
|